Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
|
|
- Virginia Griffin
- 5 years ago
- Views:
Transcription
1 Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy Services, University Health System Pharmacotherapy Division, the University of Texas at Austin College of Pharmacy Pharmacotherapy Education and Research Center, University of Texas San Antonio March 8 th, 2019 Learning Objectives: 1. Describe the disease state, classification, and current guideline recommended management of asthma 2. Discuss adherence and complications associated with asthma 3. Review the current literature regarding using inhaled corticosteroids as needed for management of mild persistent asthma 4. Summarize when using inhaled corticosteroids as needed is appropriate for mild persistent asthma
2 Assessment questions: 1. What is the American guideline recommended 1 st line maintenance treatment for mild persistent asthma? A. Inhaled corticosteroid B. Long-acting beta 2 agonist C. Theophylline D. Leukotriene receptor antagonist 2. What estimated percent of patients with asthma are adherent to their maintenance inhaler regimen? A. 5-10% B % C % D % 3. True or False: Inhaled corticosteroids used as needed demonstrated similar control of symptoms and exacerbations to daily inhaled corticosteroids in the SYGMA trials. A. True B. False ***To Obtain CE credit for attending this program please sign in. Attendees will be ed a link to an electronic CE Evaluation Form. CE credit will be awarded upon completion of the electronic form. If you do not receive an within 72 hours, please contact the CE Administrator at ana.francomartinez@uhs-sa.com*** Faculty (Speaker) Disclosure: Lindsay Thomas has indicated she has no relevant financial relationships relative to the content of her presentation. Thomas 2
3 Background Asthma is a chronic inflammatory disorder of the airways 1-3 Common characteristics: episodic airflow limitation, bronchial hyperresponsiveness, underlying inflammation, and reversible airway obstruction Symptoms: wheezing, breathlessness, cough, chest tightness Epidemiology in the United States 4,5 Prevalence (2016): 26,515,000 Asthma related deaths (2016): 3,518 /year Persons having > 1 asthma attack (2016): 12,426,000/year Asthma related inpatient hospital discharges (2010): 439,435/year Asthma related emergency department visits (2015): 1,700,000/year Asthma related physician visits (2014): 11,000,000/year Pathophysiology 1-3 Airway inflammation is a major factor in determining severity, cell/mediator pattern, and treatment response Recurrent airflow limitation is caused by a variety of changes o Bronchoconstriction: can be induced by allergens, medications (e.g., aspirin, nonsteroidal anti-inflammatory drugs), exercise, cold air, irritants (e.g., chemicals, tobacco smoke) o Airway edema o Airway hyperresponsiveness o Airway remodeling Diagnosis 1-3,6-8 Must determine presence of episodic airflow obstruction and airway hyperresponsiveness symptoms, at least partially reversible airflow obstruction, exclusion of other diagnosis Tools used for diagnosis o Detailed medical history o Physical examination of upper respiratory tract, chest, and skin o Spirometry (Appendix A, Section a) 5 o Patient Assessment Questionnaires (Appendix A, Section b) 6-7 Classification (Appendix B) 1-3 Four classes 1. Intermittent 3. Moderate persistent 2. Mild persistent 4. Severe persistent Considers o Frequency of symptoms o Nighttime awakenings due to asthma symptoms o Use of short-acting beta 2 agonist (SABA) o Interference with normal activity o Lung function o Exacerbation requiring systemic corticosteroids Thomas 3
4 Treatment 1-3 Goals o o Reduce impairment of daily activities Prevent symptoms Maintain normal pulmonary function Maintain normal activity levels Reduce risk of exacerbation Minimize need of emergency department (ED) visits or hospitalizations Prevent progressive loss of lung function Use the stepwise approach to determine medication therapy (Table 1) o Initial step is based on asthma classification (Figure 1, Appendix C) o Use stepwise approach to make medication adjustments Assess asthma control (Appendix D) Initial: every 2-6 weeks until controlled Maintenance: every 1-6 months To step up Address the following considerations: quality of life impairment, risk of exacerbation, adherence, environmental control, comorbid conditions To step down, patient MUST be well-controlled for 3 months Figure 1: Stepwise approach to therapy Source: figure 16. Summary report Guidelines for the diagnosis and management of asthma. NHLBI Thomas 4
5 1-3, 9-45 Table 1: Medication classes Beta 2 Agonists Medications SABAs: albuterol, levalbuterol, terbutaline LABAs: formoterol (similar time of onset as short-acting), salmeterol, vilanterol MOA agonize beta 2 receptors which increases camp leading to relaxation of airway smooth muscle AE tachycardia, QTc prolongation, hypokalemia, tremor, hyperglycemia Place in therapy SABAs: rescue therapy LABAs: used in combination with ICS for long-term control of asthma CANNOT be used as monotherapy in asthma Inhaled Corticosteroids Medications budesonide, fluticasone, beclomethasone, mometasone, ciclesonide MOA block late-phase reaction to allergen, reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation AE oral candidiasis, dysphonia, reflex cough, bronchospasm, and reduction in growth rate (children and adolescents) Place in therapy long-term control of asthma for mild, moderate, or severe persistent asthma (monotherapy or in combination) Anticholinergics Medications short-acting: ipratropium long-acting: tiotropium MOA inhibit muscarinic cholinergic receptors leading to bronchodilation AE dry mouth, increase wheezing, blurred vision, decreased respiratory secretions Place in therapy short-acting: moderate or severe asthma exacerbations in ED with SABA long-acting: tiotropium is FDA approved and currently recommended by GINA Leukotrienes Receptor Antagonists Medications montelukast, zafirlukast MOA block the effects of leukotrienes leading to reduce inflammation AE headache, dizziness, fatigue, skin rash, cough Place in therapy alternative (NOT preferred) for long-term control of mild persistent asthma; use as adjunctive therapy with ICS 5-Lipoxygenase Inhibitor Medications zileuton, zileuton CR MOA inhibits production of leukotriene leading to reduce inflammation AE elevated liver enzymes, hepatitis, hyperbilirubinemia Place in therapy alternative for adults (less preferred than LTRAs) Mast Cell Stabilizer Medications cromolyn MOA stabilize mast cells and eosinophil recruitment, interfere with chloride channel function AE chest pain, edema, headache, irritability, skin rash, photosensitivity, diarrhea, nausea, abdominal pain, constipation, neutropenia Place in therapy alternative (NOT preferred) for long-term control of mild persistent asthma Methylxanthines Medications theophylline MOA non-selectively inhibits phosphodiesterase leading to bronchodilation AE headache, nausea/vomiting, tachycardia, insomnia, hyperglycemia, hypokalemia, gastric upset, seizures Place in therapy alternative (NOT preferred) for long-term control of mild persistent asthma; use as adjunctive therapy with ICS (NOT preferred) Thomas 5
6 Immunomodulators Medications benralizumab, mepolizumab, omalizumab, reslizumab AE pain and bruising at injection site, anaphylaxis, malignant neoplasms Place in therapy long-term control of moderate or severe persistent allergic asthma inadequately controlled with ICS SABA: short-acting beta 2 agonist; LABA: long-acting beta 2 agonist; MOA: mechanism of action; AE: adverse effects; camp: cyclic adenosine monophosphate; ICS: inhaled corticosteroids; FDA: Food and Drug Administration; GINA: Global Initiative for Asthma; ED: emergency department; LTRA: leukotriene receptor antagonist; CR: controlled release Adherence 1-3,46 Estimated adherence to inhale corticosteroids (ICS) maintenance therapy in asthma: 22-63% o Risk factors for nonadherence: children and adolescents, African Americans, mild asthma, low education level, and poor communication with healthcare providers Implications: higher percentage of eosinophils in sputum, increased use of oral corticosteroids increased hospitalization, higher mortality rate Complications 1-3 Exacerbations (see Appendix F for risk factors) Pneumonia Respiratory failure Death Literature Evaluating ICS as Needed in Asthma A 2013 Cochrane meta-analyses included 6 trials (n=1211) that evaluated ICS + SABA as needed (PRN) vs ICS maintenance therapy 47 Rates of exacerbation: ICS + SABA PRN had similar to ICS maintenance therapy Lung function, airway inflammation, asthma control, and reliever use: ICS maintenance therapy was superior to ICS + SABA PRN Table 2. O Byrne PM, et al. Inhaled combined budesonide-formoterol as needed in mild asthma (SYGMA 1). N Engl J Med. 2018;378: Objective To assess the long-term efficacy and safety of budesonide-formoterol PRN in mild persistent asthma Methods Design 52-week double-blind, randomized, parallel group, phase 3 trial involving patient > 12 years old with mild persistent asthma Population Inclusion criteria Exclusion criteria > 12 years old Worsening asthma within 30 days that Received asthma diagnosis > 6 required medication changes months before enrollment Use of systemic steroids within 30 days Needed GINA step 2 therapy > 30 Use of any ß-blocking agents days before visit 2 Smoker with > 10 pack-year History of life-threatening asthma Intervention 3 groups 1. Terbutaline PRN: placebo BID + terbutaline (0.5 mg) PRN 2. Budesonide-formoterol PRN: placebo BID + budesonide-formoterol (200 mcg/6mcg) PRN 3. Budesonide maintenance: budesonide (200 mcg) BID + terbutaline (0.5 mg) PRN Thomas 6
7 Primary outcomes Secondary outcomes Results Baseline characteristics Determine superiority of budesonide-formoterol used as needed over terbutaline used as needed in terms of asthma symptom scores, nighttime awakenings, morning peak expiratory flow, additional use of inhaled or systemic glucocorticoids Determine noninferiority of budesonide-formoterol used as needed to budesonide maintenance therapy in terms of weeks of well-controlled asthma, comparing rates and time to the 1 st severe exacerbation, rates and time to 1 st moderate-to-severe exacerbation, AQLQ, and ACQ-5 Safety (type, incidence, and severity of adverse events and by monitoring of vital signs) n=3836 Characteristic Terbutaline PRN (n=1277) Budesonideformoterol PRN (n=1277) Budesonide maintenance (n=1282) Age years +STD Female sex n(%) 771 (60.4) 777 (60.8) 797 (62.2) Time since asthma 6.3 ( ) 6.5 ( ) 6.3 ( ) diagnosis years (range) ACQ-5 mean score +STD At trial entry At baseline ACQ-5 score > 1.5 n/total n(%) At trial entry At baseline 549/1160 (47.3) 602/1256 (47.9) 601/1174 (51.2) 649/1257 (51.6) AQLQ score +STD FEV 1 % of predicted value +STD Before bronchodilator use After bronchodilator use PEF > 80% predicted value in AM n/total n(%) Bronchodilator reversibility % +STD 568/1177 (48.3) 596/1257 (47.4) /1276 (28.4) 340/1277 (26.6) 376/1282 (29.3) Thomas 7
8 Primary outcome Asthma control according to pretrial treatment Uncontrolled with SABA alone n(%) Controlled with ICS or LTRA n(%) 565 (44.2) 712 (55.8) 565 (44.2) 712 (55.8) 576 (44.9) 706 (55.1) Severe exacerbation in previous 12 months n(%) 256 (20.0) 257 (20.1) 241 (18.8) Mean percentage of electronically recorded weeks with well-controlled asthma per patient in budesonide-formoterol group vs. terbutaline group: 34.4% vs 31.1% of weeks; OR: 1.14; 95% CI: ; p=0.046 Secondary outcome Mean percentage of electronically recorded weeks with well-controlled asthma per patient in budesonide-formoterol PRN group vs. budesonide maintenance group: 34.4% vs 44.4% of weeks; OR: 0.64; 95% CI: Rate of severe exacerbation budesonide-formoterol PRN group vs. terbutaline PRN group: 0.07 vs 0.20; RR: 0.36; 95% CI: Rate of severe exacerbation budesonide-formoterol PRN group vs. budesonide maintenance group: 0.07 vs 0.09; RR: 0.83; 95% CI: Time to 1 st exacerbation budesonide-formoterol PRN group vs. terbutaline PRN group: HR: 0.44, 95% CI: Time to 1 st exacerbation budesonide-formoterol PRN group vs. budesonide maintenance group: HR: 0.9; 95% CI: Adverse events increased in terbutaline PRN group o Terbutaline PRN group 545 (42.7%) o Budesonide-formoterol PRN group 485 (38.0%) o Budesonide maintenance group 512 (39.9%) Author s Conclusion Budesonide-formoterol PRN was superior to terbutaline PRN both for asthma symptom control and for reducing the risk of asthma exacerbations among patients with mild persistent asthma. Budesonide-formoterol PRN was inferior to budesonide maintenance therapy with asthma symptom control. However, budesonide-formoterol had similar reduction of exacerbation risk to budesonide maintenance therapy, at a substantially lower total glucocorticoid load and without the need to adhere to a BID maintenance therapy schedule. Thomas 8
9 Reviewer s Critique Strengths: Groups were similar 52-week duration Used electronic monitoring that required real-time recording Kept tract of ICS exposure Adherence ~80% Limitations: Terbutaline PRN is not the guideline recommended treatment for mild persistent asthma ICS PRN group included a fast-acting LABA Adherence ~80% Conclusion: Budesonide-formoterol PRN superior to terbutaline PRN in controlling mild persistent asthma Budesonide-formoterol PRN inferior to budesonide BID in controlling symptoms even though time to 1 st exacerbation was similar Budesonide-formoterol PRN had less ICS and systemic steroid GINA: Global Initiative for Asthma; BID: twice daily; PRN: as needed; AQLQ: Asthma Quality of Life Questionnaire; ACQ: Asthma Control Questionnaire; STD: standard deviation; FEV 1: forced expiratory volume in 1 second; PEF: peak expiratory flow; CI: confidence interval; OR: odds ratio; RR: rate ratio; HR: hazard ratio; ICS: inhaled corticosteroid; SABA: short-acting beta 2 agonist; LTRA: leukotriene receptor antagonist Table 3. Bateman ED, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma (SYGMA 2). N Engl J Med. 2018;378: Objective To determine if budesonide formoterol PRN is non-inferior to regular budesonide maintenance treatment in preventing severe exacerbations in patients with mild asthma Methods Design 52-week double-blind, randomized, parallel group, phase 3 trial involving patient > 12 years old with mild persistent asthma Population Inclusion criteria Exclusion criteria Intervention Primary outcomes Secondary outcomes Results Baseline characteristics > 12 years old Received asthma diagnosis > 6 months before enrollment Needed GINA step 2 therapy > 30 days before visit Asthma worsening that involved a change in treatment or use of glucocorticoids in previous 30 days History of > 10 pack-years History of life-threatening asthma 2 groups 1. Budesonide-formoterol PRN: placebo BID + budesonide-formoterol (200 mcg/6mcg) PRN 2. Budesonide maintenance: budesonide (200 mcg) BID + terbutaline (0.5 mg) PRN Annualized rate of severe exacerbation in both groups Time to severe exacerbation Use of inhaled and systemic glucocorticoids FEV 1 before bronchodilator use Trial specific asthma-related discontinuation Use of maintenance therapy and as-needed reliever therapy The percentage of reliever-free days ACQ-5 score, AQLQ score N=4176 Characteristic Age years Mean +STD Range Budesonideformoterol PRN (n=2089) Budesonide maintenance (n=2087) Thomas 9
10 Primary outcome Female sex n(%) 1208 (62.6) 1289 (61.8) Current smoking n(%) 53 (2.5) 54 (2.6) Time since asthma diagnosis years 7.9 ( ) 7.3 ( ) Median (range) ACQ-5 mean score +STD ACQ-5 score > 1.5 n/total n(%) 943/2043 (46.2) 1000/2037 (49.1) FEV 1 % of predicted value + STD Before bronchodilator use After bronchodilator use Bronchodilator reversibility % +STD Asthma control according to pretrial treatment Uncontrolled with SABA alone n(%) Controlled with ICS or LTRA n(%) Severe exacerbation in previous 12 months n(%) 0 1 > (45.9) 1130 (54.1) 1630 (78.0) 365 (17.5) 94 (4.5) 975 (46.7) 1112 (53.3) 1627 (78.0) 362 (17.3) 98 (4.7) Secondary outcome Use of inhaled and systemic glucocorticoids o Median daily dose in budesonide-formoterol group was 66 mcg and in budesonide maintenance group was 267 mcg (75% increase) Thomas 10
11 Author s Conclusion In patients with mild asthma, budesonide formoterol used as needed was noninferior to twice-daily budesonide with respect to the rate of severe asthma exacerbations during 52 weeks of treatment but was inferior in controlling symptoms. Patients in the budesonide formoterol group had approximately one quarter of the inhaled glucocorticoid exposure of those in the budesonide maintenance group. Reviewer s Critique Strengths: Compared to guideline recommended therapy Similar baseline characteristics Looked at steroid exposure (ICS and systemic steroids) Limitations: Adherence ~64% in maintenance group Did not assess markers of inflammation Conclusion: ICS maintenance therapy is better than ICS PRN ICS PRN has lower corticosteroid exposure GINA: Global Initiative for Asthma; BID: twice daily; PRN: as needed; AQLQ: Asthma Quality of Life Questionnaire; ACQ: Asthma Control Questionnaire; STD: standard deviation; FEV 1: forced expiratory volume in 1 second; PEF: peak expiratory flow; CI: confidence interval; OR: odds ratio; RR: rate ratio; HR: hazard ratio; ICS: inhaled corticosteroid; SABA: short-acting beta 2 agonist; LTRA: leukotriene receptor antagonist Thomas 11
12 Table 4. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet. 2011;377: Objective To establish whether discontinuation of daily inhaled corticosteroids in children with well controlled, mild persistent asthma is associated with an increased risk of exacerbations, and whether or not the use of beclomethasone plus albuterol for relief, with or without concomitant use of daily beclomethasone, provides better protection against exacerbations than does a rescue strategy that uses albuterol alone. Methods Design A 44-week randomized, double-blind, four-treatment trial with a 2x2 factorial design Population Inclusion criteria Exclusion criteria Between 6 and 18 years old Pre-bronchodilator FEV 1 <60% of predicted Naive to controller treatment and at 1 st visit had a history of 1-2 exacerbations in previous year Hospitalization due to asthma in previous year Treated for the previous 8 weeks with a monotherapy other than ICS Any asthma exacerbation in previous 3 months or > 2 in the previous year Their illness was controlled for previous 8 weeks on low-dose corticosteroids as monotherapy (< 160 mcg daily with beclomethasone equivalent) History of life-threatening asthma exacerbations that required intubation or mechanical ventilation or resulted in a hypoxic seizure Intervention 4 groups 1. Combined: beclomethasone BID + beclomethasone/albuterol PRN 2. Daily: beclomethasone BID + placebo/albuterol PRN 3. Rescue: placebo BID + beclomethasone/albuterol PRN 4. Placebo: placebo BID + placebo/albuterol PRN Primary Time to first exacerbation that required treatment with prednisone outcome Secondary FEV 1, FENO, symptom diaries and control and quality of life questionnaires, linear growth outcomes Results Baseline characteristics N=288 Characteristic Combined Daily (n=72) Rescue Placebo (n=74) (n=71) (n=71) Age years +STD Sex (male) n(%) 39 (55) 42 (58) 37 (52) 41 (55) White n(%) 50 (70) 51 (71) 57 (80) 59 (78) Height cm +STD Weight kg +STD Age at asthma diagnosis years +STD Age at onset of asthma symptoms years +STD ICS use in previous 54 (76) 59 (82) 51 (72) 57 (77) year n(%) LTRA use in previous 11 (16) 7 (10) 14 (20) 13 (18) n(%) > 1 steroid course in last year n(%) 19 (27) 19 (26) 24 (34) 21 (28) Thomas 12
13 Primary outcome Pre-bronchodilator FEV 1 % predicted +STD FEV 1 /FVC % +STD Hospital visit in previous year Mean +STD Secondary outcome Probability of 1 st exacerbation by the end of the trial: Combined: 31% Daily: 28% Rescue: 35% Placebo: 49% Frequency of exacerbation Placebo vs Daily: 49% vs. 28%, p=0.03 Placebo vs Combined: 49% vs. 31%, p=0.07 Placebo vs Rescue: 49% vs. 35%, p=0.07 Linear growth Placebo and rescue: 1.1 cm more of growth than combined and daily (p<0.0001) FEV 1 : no difference among groups in decline of FEV 1 FENO: increase in the rescue and placebo groups vs daily and combined groups (p<0.0001) Thomas 13
14 Author s Conclusion Children with mild persistent asthma should not be treated with rescue albuterol alone and the most effective treatment to prevent exacerbations is daily inhaled corticosteroids. Inhaled corticosteroids as rescue medication with albuterol might be an effective step-down strategy for children with well controlled, mild asthma because it is more effective at reducing exacerbations than is use of rescue albuterol alone. Use of daily inhaled corticosteroid treatment and related side-effects such as growth impairment can therefore be avoided. Reviewer s Critique Strengths: 4 different treatment arms Evaluated linear growth Children and adolescents only Limitations: Smaller study Children and adolescents only Deviated from original analysis plan due to subadditive interactions Conclusion: ICS daily should be our first choice to reduce exacerbations in mild persistent asthma ICS daily with PRN ICS + SABA demonstrated best control of asthma If growth impairment or ICS exposure is a concern, ICS PRN could be considered BID: twice daily; PRN: as needed; AQLQ: Asthma Quality of Life Questionnaire; ACQ: Asthma Control Questionnaire; STD: standard deviation; FEV 1: forced expiratory volume in 1 second; FENO: fractional exhaled nitric oxide; FVC: forced vital capacity; CI: confidence interval; OR: odds ratio; RR: rate ratio; HR: hazard ratio; ICS: inhaled corticosteroid; SABA: short-acting beta 2 agonist When is using ICS PRN as monotherapy appropriate? In mild persistent asthma, ICS maintenance therapy + SABA or ICS/SABA PRN should be 1 st line BUT, if the patient meets the following criteria, ICS PRN could be used o Asthma has been well-controlled for more than 3 months o Patient is non-adherent to ICS o Growth impairment is a concern Take home points 1. Over 26 million Americans have asthma 2. The recommended treatment for mild persistent asthma is ICS maintenance therapy + SABA PRN 3. All 3 trials demonstrated ICS maintenance therapy provided better control of symptoms than ICS PRN Summary BUT, all 3 found similar rates of exacerbation between ICS maintenance therapy and ICS PRN 4. ICS PRN could be used in well-controlled mild persistent asthma in adolescents to limit ICS exposure and growth impairment References 1. National Asthma Education and Prevention Program. Expert Panel Report 3. Guidelines for the diagnosis and management of asthma. NHLBI National Asthma Education and Prevention Program. Expert Panel Report 3. Summary report: guidelines for the diagnosis and management of asthma. NHLBI Global Initiative for Asthma (GINA). GINA report, global strategy for asthma management and prevention Asthma: most recent asthma data. CDC Accessed January 4, 2019 Thomas 14
15 5. Asthma facts and figures. AAFA Accessed January 4, Lung procedures and tests: spirometry. American Lung Association Accessed January 10, Asthma control questionnaire (ACQ). American Thoracic Society Accessed January 10, Asthma quality of life questionnaire (AQLQ). American Thoracic Society Accessed January 10, ProAir HFA (albuterol) [prescribing information]. Horsham, PA: Teva Specialty Pharmaceuticals LLC; Jul ProAir RespiClick (albuterol) [prescribing information]. Horsham, PA: Teva Specialty Pharmaceuticals LLC; Aug Proventil HFA (albuterol [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; Dec Ventolin (albuterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May Xopenex HFA (levalbuterol) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; Feb Atrovent HFA (ipratropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; Aug Combivent Respimat (ipratropium bromide and albuterol) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; Jun Alvesco (ciclesonide) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; Mar Arnuity Ellipta (fluticasone furoate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Jan Asmanex HFA (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck & Co; Mar Asmanex Twisthaler (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck & Co; Mar Flovent Diskus (fluticasone propionate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Jan Flovent HFA (fluticasone propionate inhalation aerosol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Jan Pulmicort Flexhaler (budesonide aerosol, powder) [prescribing information] Södertälje, Sweden: AstraZeneca; Oct Qvar RediHaler (beclomethasone) [prescribing information]. Frazer, PA: Teva Respiratory; Mar Serevent Diskus (salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Dec Spiriva HandiHaler (tiotropium bromide) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; Feb Spiriva Respimat (tiotropium bromide) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; May Advair Diskus (fluticasone/salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Jan Advair HFA (fluticasone/salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Dec AirDuo RespiClick (fluticasone/salmeterol) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; Mar Breo Ellipta (fluticasone/vilanterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Dec Dulera (mometasone/formoterol) [prescribing information]. Whitehouse Station, NJ: Merck and Co Inc; Jul Symbicort (budesonide/formoterol) [prescribing information]. Wilmington, DE: AstraZeneca LP; Dec Symbicort Turbuhaler (budesonide/formoterol) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; Oct Nelson HS, et al; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1): Peters SP, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med. 2016;375(9): Singulair (montelukast) [prescribing information]. Whitehouse Station, NJ: Merck and Co; December Accolate [package insert]. Wilmington, DE: AstraZeneca; Nov Zyflo (zileuton) [prescribing information]. Cary, NC: Chiesi USA, Inc; May Zyflo CR (zileuton) [prescribing information]. Cary, NC: Chiesi USA, Inc; Dec Cromolyn Sodium (oral solution) [prescribing information]. Mason, OH: Prasco Laboratories; Dec Theophylline in 5% dextrose [package insert]. Bethlehem, PA: B. Braun Medial Inc; Jan Fasenra (benralizumab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; Nov Nucala (mepolizumab) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; Jul Xolair (omalizumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; Sep Cinqair (reslizumab) [prescribing information]. Frazer, PA: Teva Respiratory; Jan Barnes CB, et al. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respiratory Care. 2015;60(3): Chauhan BF, et al. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2013;(2):CD O Byrne PM, et al. Inhaled combined budesonide-formoterol as needed in mild asthma(sygma 1). N Engl J Med. 2018;378: Thomas 15
16 49. Bateman ED, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma (SYGMA 2). N Engl J Med. 2018;378: Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet. 2011;377: Appendix A. Diagnosis tools a. Spirometry: assesses severity of obstruction and reversibility of obstruction 5 i. May be used in children > 5 years old ii. The following are recommended before and after taking SABA for diagnosis: 1. Forced expiratory volume in 1 second (FEV 1 ): volume of air a patient can exhale forcefully in one second a. Reduced value: significant obstruction b. Can help determine reversibility i. Increase of FEV 1 by > 12% from baseline ii. Increase of predicted FEV 1 by > 10% after inhalation of SABA 2. Forced expiratory volume in 6 seconds (FEV 6 ) [only used in adults] a. Reduced value: restricted breathing 3. Forced vital capacity (FVC): largest volume of air a patient can exhale forcefully a. Reduced value: restricted breathing 4. FEV 1 /FVC a. Increased value: restricted breathing b. Reduced value: obstructed breathing b. Patient Assessment Questionnaires 6-7 i. Asthma Control Questionnaire (ACQ) items: symptoms, rescue inhaler use, and FEV 1 % 2. 1-week recall 3. 7-point scale a. 0: no impairment b. 6: maximum impairment for symptoms and rescue use ii. Asthma Quality of Life Questionnaire (AQLQ) domains: symptoms, activity limitation, emotional function, and environmental exposure week recall 3. 7-point scale a. 1: severely impaired b. 7: no impairment Thomas 16
17 B. Classifications 1,2 Source: figure 14. Summary report Guidelines for the diagnosis and management of asthma. NHLBI C. GINA Stepwise management for patients > 12 years old 3 Thomas 17
18 D. Determining asthma control 1,2 Source: figure 15. Summary report Guidelines for the diagnosis and management of asthma. NHLBI E. Medications Table E-1: Asthma Inhalers Available in United States 9-35 Name Components Dosing Type of Inhaler Short-Acting Beta 2 Agonist (SABA) ProAir Albuterol sulfate 2 puffs every 4-6 MDI ProAir RespiClick hours PRN wheezing DPI Proventil or SOB MDI Ventolin MDI Xopenex Levalbuterol 2 puffs every 4 to 6 MDI hours PRN Short-Acting Anti-Muscarinic Agents (SAMA) Atrovent Ipratropium bromide 8 puffs every 20 MDI minutes PRN Combivent Respimat Ipratropium bromide + 8 puffs every 20 SMI albuterol sulfate minutes PRN Maintenance or Rescue Rescue Rescue Rescue* Rescue* Inhaled Corticosteroids (ICS) Alvesco Ciclesonide BID MDI Maintenance Arnuity Ellipta Fluticasone furoate QD DPI Maintenance Asmanex Mometasone furoate BID MDI Maintenance Asmanex Twisthaler QD or BID DPI Flovent Fluticasone propionate BID MDI Maintenance Flovent Diskus BID DPI Pulmicort Flexhaler Budesonide BID DPI Maintenance QVAR RediHaler Beclomethasone dipropionate BID MDI Maintenance Thomas 18
19 Long-Acting Beta 2 Agonist (LABA) Serevent Diskus Salmeterol xinafoate BID MDI Maintenance** Long-Acting Anti-Muscarinic Agent (LAMA) Spiriva Respimat Tiotropium bromide QD SMI Maintenance Spiriva HandiHaler QD MDI Combination: ICS + LABA Advair Fluticasone propionate + BID MDI Maintenance Advair Diskus salmeterol BID DPI Airduo RespiClick Fluticasone propionate + BID DPI Maintenance salmeterol Breo Ellipta Fluticasone furoate + QD DPI Maintenance vilanterol Dulera Mometasone furoate + BID MDI Maintenance formoterol fumarate Symbicort Turbuhaler Budesonide + formoterol fumarate QD or BID DPI Maintenance *Not recommended for rescue therapy outside the emergency room or urgent care settings; **Must be used with an ICS PRN: as needed; SOB: shortness of breath; MDI: metered-dose inhalers; DPI: dry powder inhaler; SMI: soft mist inhaler; QD: once daily; BID: twice daily Table E-2: Low, Medium, and High doses of ICS inhalers for patients > 12 years old 3,16-23 ICS Low Medium High Beclomethasone dipropionate (HFA) >400 Budesonide (DPI) >800 Ciclesonide (MDI) >320 Fluticasone furoate (DPI) 100 n/a 200 Fluticasone propionate (MDI, DPI) >500 Mometasone furoate (MDI, DPI) >440 MDI: metered-dose inhalers; DPI: dry powder inhaler F. Exacerbation risk factors 1-3 Severe airflow obstruction Persistent airflow obstruction > 2 ED visits or hospitalizations for asthma in last year History of intubation or intensive care units admissions in last 5 years Feeling in danger or frightened by asthma Female Nonwhite Current tobacco smoker Not using ICS Depression Increased stress Socio economic factors Attitudes and beliefs about medications Thomas 19
12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationBrooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C
Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C Associate Professor of Pharmacy Practice Southwestern Oklahoma State University College of Pharmacy Oklahoma Society of Health System Pharmacists Annual Meeting
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationAsthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma
Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care
More informationRespiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationReference Guide for Caring for Pediatric Patients with Asthma
Reference Guide for Caring for Pediatric Patients with Asthma Co-Chair: Nancy Cantey Banasiak, DNP, PPCNP-BC, APRN Co-Chair: Deborah Hickman, DNP, APRN-CNP, CPNP-PC, NNP-BC Asthma and Allergy SIG Members
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationDrugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationEffective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017
Protocol Title: Adult Asthma Protocol Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 1 Purpose & Objective This protocol provides evidence-based
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationcontinuing education for pharmacists
continuing education for pharmacists Volume XXXIV, No. 12 Asthma: Approaches to Treatment and New Therapies Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationASTHMA BEST PRACTICES FOR SCHOOL NURSES. School Nurses November 2015
ASTHMA BEST PRACTICES FOR SCHOOL NURSES School Nurses November 2015 1 BACKGROUND AND CURRENT STATS General definitions and explanations 2 Incidence of Asthma Centers for Disease Control (CDC) - 1 in 12
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAsthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationCombination Beta2-Agonist/Corticosteroid Inhalers
Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationAdult Asthma Clinical Practice Guideline Summary
Adult Asthma Clinical Practice Guideline Summary The following evidence-based guideline was developed to assist Primary Care physicians and other clinicians in the management of asthma in adults. It was
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More informationAsthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More information1.* Dosage. A. Adults
Aerosolized Agents (Metered-Dose Inhalers) - Inhaled Anti-Inflammatory Drugs: Corticosteroids [Developed, January 1995; Revised, February, 1997; August 1997; March 1998; February 1999; January 2000; March
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationTaking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP
Taking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP Associate Dean for Clinical Education and External Affiliations & Professor
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationAerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More information